For in vitro diagnostic use. Others MDN2 IVD MDN2 CPS_000168 ONLINE DAT Methadone II 04 490 851 190 4 490 851 190 04490851190 4490851190 04490851190 MDN2, 200T, cobas c MDN2 04015630997749 Reagents, kits 200 tests cobas c 311/501/502 true 06 334 482 190 6 334 482 190 06334482190 6334482190 06334482190 MDN2, 100T, cobas c 701/702 MDN2 04015630930333 Reagents, kits 100 tests cobas c 701/702 true 08 058 008 190 8 058 008 190 08058008190 8058008190 08058008190 MDN2, 850T, cobas c pack green MDN2 07613336121405 Reagents, kits 850 tests cobas c 303/503/703 true 04490851500 MDN2 ONLINE DAT Methadone II en 14 FF00000006BF680E FF0000000061660E 04490851190 309 cobas c 501 2324 cobas c 502 308 cobas c 311 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Application in urineMethadone II (MDN2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methadone in human urine on cobas c systems at a cutoff concentration of 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Methadone II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.Application in serum and plasma**not available in all countriesThe ONLINE DAT II assay for Methadone is an in vitro diagnostic test for the qualitative detection of methadone in human serum and plasma on cobas c systems at a cutoff concentration of 300 ng/mL.The assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1704490851190c501sp MDN2 ONLINE DAT Methadone II en 4 FF000000047FF30E FF00000001D5510E 04490851190 309 cobas c 501 2324 cobas c 502 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use The ONLINE DAT II assay for Methadone is an in vitro diagnostic test for the qualitative detection of methadone in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 300 ng/mL. The assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 06334482500 MDN2 Methadone II en 6 FF000000069E310E FF00000000657A0E 06334482190 310 cobas c 701 2492 cobas c 702 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Methadone II (MDN2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methadone in human urine on cobas c systems at a cutoff concentration of 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Methadone II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0108058008190c503 MDN2 ONLINE DAT Methadone II en 5 FF00000004F2B70E FF00000004D6E80E 08058008190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Methadone II (MDN2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methadone in human urine on Roche/Hitachi cobas c systems at a cutoff concentration of 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Methadone II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0008058008190c503 MDN2 ONLINE DAT Methadone II en 4 FF0000000480640E FF00000003901B0E 08058008190 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Methadone II (MDN2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methadone in human urine on Roche/Hitachi cobas c systems at a cutoff concentration of 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Methadone II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1708058008190c503sp MDN2 ONLINE DAT Methadone II en 4 FF00000004805E0E FF000000036F2A0E 08058008190 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use The ONLINE DAT II assay for methadone is an in vitro diagnostic test for the qualitative detection of methadone in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 300 ng/mL. The assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 08058008500 MDN2 ONLINE DAT Methadone II en 6 FF000000069EBB0E FF00000004D5920E 08058008190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Application in urineMethadone II (MDN2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methadone in human urine on cobas c systems at a cutoff concentration of 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Methadone II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.Application in serum and plasma**not available in all countriesThe ONLINE DAT II assay for Methadone is an in vitro diagnostic test for the qualitative detection of methadone in human serum and plasma on cobas c systems at a cutoff concentration of 300 ng/mL. The assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en

User profile

Select your user profile

MDN2

Overview

Ordering information

Technical documents

Compatible products

Contact us